摘要
目的:比较阿柏西普和雷珠单抗治疗视网膜静脉阻塞(RVO)患者的效果。方法:回顾性分析2021年1月1日-10月31日就诊于汕头大学医学院附属粤北人民医院60例RVO继发黄斑水肿(ME)患者,将患者按给药种类分为雷珠单抗组和阿柏西普组,各30例。雷珠单抗组使用玻璃体腔内注射雷珠单抗,阿柏西普组使用玻璃体腔内注射阿柏西普。比较两组LogMAR BCVA、黄斑中心凹视网膜厚度(CMT)、浅层毛细血管丛(SCP)和深部毛细血管丛(DCP)的黄斑毛细血管密度、额外注射次数及不良反应的发生情况。结果:两组基线LogMAR BCVA、CMT比较,差异均无统计学意义(P>0.05);与基线值相比,两组治疗后1、3、6个月的LogMAR BCVA、CMT均下降,且阿柏西普组LogMAR BCVA均较雷珠单抗组低(P<0.05)。两组治疗后1个月的CMT比较,差异无统计学意义(P>0.05)。但治疗后3个月和6个月,阿柏西普组CMT均低于雷珠单抗组(P<0.05)。两组基线SCP和DCP黄斑毛细血管密度比较,差异均无统计学意义(P>0.05);治疗后1、3、6个月,两组SCP和DCP黄斑毛细血管密度比较,差异均无统计学意义(P>0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。阿柏西普组额外平均注射次数少于雷珠单抗组(P=0.010)。结论:阿柏西普较雷珠单抗能更有效改善视网膜静脉阻塞继发黄斑水肿患者的BCAV和CMT,且重复注射次数少,可以减少治疗负担,安全有效。
Objective:To compare the efficacy of Aflibercept and Ranizumab in patients with retinal vein occlusion(RVO).Method:A total of 60 patients with macular edema(ME)secondary to RVO admitted to North Guangdong People’s Hospital Affiliated the Medical College of Shantou University from January 1st to October 31st,2021 were retrospectively analyzed,and the patients were divided into Ranizumab group and Aflibercept group according to drug administration type,30 cases in each group.The Ranizumab group was given intravitreal injection of Ranizumab,and the Aflibercept group was given intravitreal injection of Aflibercept.LogMAR BCVA,macular fovea retinal thickness(CMT),superficial capillary plexus(SCP)and deep capillary plexus(DCP)macular capillary density,additional injection times and the occurrence of adverse reactions were compared between the two groups.Result:There were no significant differences in baseline LogMAR BCVA and CMT between the two groups(P>0.05);compared with baseline values,LogMAR BCVA and CMT decreased in both groups at 1,3 and 6 months after treatment,and LogMAR BCVA in the Aflibercept group were lower than those in the Ranizumab group(P<0.05).There were no significant differences in CMT between the two groups 1 month after treatment(P>0.05).However,at 3 and 6 months after treatment,CMT in the Aflibercept group were lower than those in the Ranizumab group(P<0.05).There was no significant difference in baseline SCP and DCP macular capillary density between the two groups(P>0.05);at 1,3 and 6 months after treatment,there were no significant differences in SCP and DCP macular capillary density between the two groups(P>0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).The average number of additional injections in the Aflibercept group was lower than that in the Ranizumab group(P=0.010).Conclusion:Aflibercept can more effectively improve BACV and CMT in patients with ME secondary to RVO than Ranizumab,and the number of repeated injections is le
作者
刘文革
李萍萍
廖武
LIU Wenge;LI Pingping;LIAO Wu(North Guangdong People's Hospital Affiliated the Medical College of Shantou University,Shaoguan 512026,China;不详)
出处
《中国医学创新》
CAS
2023年第6期37-41,共5页
Medical Innovation of China
